Overview
- Bank of America upgraded UnitedHealth to Buy and raised its price target to $450 on Thursday, and Morgan Stanley raised its target to $453 the same day, prompting a jump in investor interest.
- BofA said its proprietary Trend Tracker showed lower medical utilization in April and May, which typically reduces insurers’ medical costs and can lift near‑term margins.
- Morgan Stanley flagged UnitedHealth’s AI adoption and operational changes at Optum as sources of longer‑term revenue and cost efficiency and estimated sizable upside to earnings if those tools scale.
- UnitedHealth shares rose roughly 5% intraday after the analyst moves and were trading near their 52‑week high, following the company’s April beat and a raised fiscal‑2026 adjusted EPS guide.
- Analysts and investors say the stock will hinge on UnitedHealth’s execution at Optum, upcoming quarterly results, and regulatory risks including Medicare Advantage funding and enforcement reviews.